Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15987297 | 0.78 | DAPK3 (0.33) | — | |
| SCHEMBL1009530 | 0.68 | DRD4 (0.42) | — | |
| SCHEMBL9594487 | 0.68 | DRD4 (0.46) | — | |
| SCHEMBL4121408 | 0.67 | ACHE (0.32) | — | |
| SCHEMBL21243961 | 0.67 | SRC (0.35) | PTPN1 | |
| SCHEMBL18822678 | 0.66 | DRD4 (0.41) | — | |
| SCHEMBL20836342 | 0.66 | GRM7 (0.43) | — | |
| SCHEMBL16416075 | 0.64 | SLC2A1 (0.36) | — | |
| SCHEMBL15505487 | 0.64 | CHEK1 (0.36) | — | |
| SCHEMBL20544402 | 0.64 | MEN1 (0.39) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250257049-A1 | HETEROCYCLIC COMPOUNDS AS MODULATORS OF MGLUR7 | PRAGMA THERAPEUTICS (FR) | 2025-08-14 | — | — | US | disclosed |
| US-12234218-B2 | Heterocyclic compounds as modulators of mGluR7 | PRAGMA THERAPEUTICS (FR) | 2025-02-25 | — | — | US | disclosed |
| CN-111148744-B | Novel heterocyclic compounds as MGLUR7 modulators | 布拉格玛治疗公司 | 2025-02-14 | — | — | CN | disclosed |
| US-20220363664-A1 | HETEROCYCLIC COMPOUNDS AS MODULATORS OF MGLUR7 | PRAGMA THERAPEUTICS (FR) | 2022-11-17 | — | — | US | disclosed |
| US-11414395-B2 | Heterocyclic compounds as modulators of mGluR7 | PRAGMA THERAPEUTICS (FR) | 2022-08-16 | — | — | US | disclosed |
| US-20200231563-A1 | NOVEL HETEROCYCLIC COMPOUNDS AS MODULATORS OF MGLUR7 | PRAGMA THERAPEUTICS (FR) | 2020-07-23 | — | — | US | disclosed |
| EP-3672950-A1 | NOVEL HETEROCYCLIC COMPOUNDS AS MODULATORS OF MGLUR7 | Pragma Therapeutics (FR) | 2020-07-01 | — | — | EP | disclosed |
| WO-2019063596-A1 | NOVEL HETEROCYCLIC COMPOUNDS AS MODULATORS OF MGLUR7 | PRAGMA THERAPEUTICS (FR) | 2019-04-04 | — | — | WO | disclosed |
| EP-3459939-A1 | NOVEL HETEROCYCLIC COMPOUNDS AS MODULATORS OF MGLUR7 | Pragma Therapeutics (FR) | 2019-03-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250257049-A1 | HETEROCYCLIC COMPOUNDS AS MODULATORS OF MGLUR7 | GRM7, GRM1, GRM2 | PTPN1 1088/4885 |
| US-20200231563-A1 | NOVEL HETEROCYCLIC COMPOUNDS AS MODULATORS OF MGLUR7 | GRM7, GRM1, GRM3 | PTPN1 1684/4885 |
| US-12234218-B2 | Heterocyclic compounds as modulators of mGluR7 | GRM7, GRM1, GRM2 | PTPN1 1088/4885 |
| US-20220363664-A1 | HETEROCYCLIC COMPOUNDS AS MODULATORS OF MGLUR7 | GRM7, GRM1, GRM2 | PTPN1 1088/4885 |
| US-11414395-B2 | Heterocyclic compounds as modulators of mGluR7 | GRM7, GRM1, GRM3 | PTPN1 1536/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.